Take This Into Account Before Investing in ABT

Large-cap Health Care company Abbott Laboratories has moved 0.6% so far today on a volume of 1,901,120, compared to its average of 5,925,307. In contrast, the S&P 500 index moved 0.0%.

Abbott Laboratories trades -9.83% away from its average analyst target price of $116.1 per share. The 20 analysts following the stock have set target prices ranging from $100.0 to $133.0, and on average have given Abbott Laboratories a rating of buy.

If you are considering an investment in ABT, you'll want to know the following:

  • Abbott Laboratories's current price is 174.5% above its Graham number of $38.14, which implies that at its current valuation it does not offer a margin of safety

  • Abbott Laboratories has moved -2.0% over the last year, and the S&P 500 logged a change of 18.0%

  • Based on its trailing earnings per share of 2.94, Abbott Laboratories has a trailing 12 month Price to Earnings (P/E) ratio of 35.6 while the S&P 500 average is 15.97

  • ABT has a forward P/E ratio of 22.6 based on its forward 12 month price to earnings (EPS) of $4.63 per share

  • The company has a price to earnings growth (PEG) ratio of -11.71 — a number near or below 1 signifying that Abbott Laboratories is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 4.85 compared to its sector average of 4.08

  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

  • Based in North Chicago, the company has 115,000 full time employees and a market cap of $181.75 Billion. Abbott Laboratories currently returns an annual dividend yield of 2.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.